ASMB
Assembly Biosciences, Inc.
ASMB's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over ASMB overall, supported by stronger fundamentals and lower modeled downside.
ASMB Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Unavailable |
ASMB's revenue is currently healthy, and its profitability is stable, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ASMB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $19.00 | -5.8% |
| Current | 20x | $20.18 | — |
| Fair | 124x | $124 | +513% |
| Expensive | 344x | $344 | +1604% |
Historical ranges are pointers, not guarantees.
ASMB has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ASMB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect ASMB's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ASMB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $1.00 | +$5.76 |
| Q2 2026 | $1.21 | +$6.76 |
| Q1 2026 | $0.08 | +$6.28 |
| Q4 2025 | -$0.55 | +$6.14 |
| Q3 2025 | -$4.76 | +$2.25 |
| Q2 2025 | -$5.55 | +$3.19 |
| Q1 2025 | -$6.20 | +$4.40 |
| Q4 2024 | -$6.69 | +$6.69 |
ASMB has returned to profit: it earned $1.00 per share over the past year, after losing money the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
ASMB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3M | -73% |
| Q2 2026 | $13.4M | +39% |
| Q1 2026 | $8.2M | -13% |
| Q4 2025 | $42.5M | +477% |
| Q3 2025 | $10.8M | +58% |
| Q2 2025 | $9.6M | +13% |
| Q1 2025 | $9.4M | +63% |
| Q3 2021 | $6.3M | -82% |
ASMB's revenue is growing: $3M last quarter, down 73% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -792% | -691 points |
| Q2 2026 | -47% | +68 points |
| Q1 2026 | -138% | -33 points |
| Q4 2025 | 47% | +203 points |
| Q3 2025 | -101% | +59 points |
| Q2 2025 | -115% | +28 points |
| Q1 2025 | -106% | +80 points |
| Q4 2024 | -157% | N/A |
ASMB's operating margin was −792% last quarter, down 691 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ASMB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ASMB on profitability, with a higher operating margin.
ASMB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17.3M | -$2.1M |
| Q2 2026 | -$15.5M | +$1.3M |
| Q1 2026 | -$22.1M | +$1.3M |
| Q4 2025 | $14.2M | +$14.6M |
| Q3 2025 | -$15.2M | +$69K |
| Q2 2025 | -$16.8M | +$358K |
| Q1 2025 | -$23.4M | -$5.1M |
| Q4 2024 | -$407K | -101% |
ASMB has burned cash in almost every quarter: −$41M over the past year, against −$56M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ASMB on cash generation, producing positive trailing cash flow while its opponent burns cash.
ASMB Net Leverage
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ASMB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 5.7 | Oversold |
ASMB's weekly RSI is 38 (neutral) and its Stochastic is 6 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ASMB PE vs Healthcare Sector
| Metric | ASMB | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 26x | 22% below |
| PE % | 26 | 29 | 3 pts below |
ASMB has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ASMB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.3 | 5.3% below |
| 20 week MA | $26.1 | 23% below |
| 50 week MA | $27.8 | 27% below |
| 100 week MA | $23.4 | 14% below |
| 200 week MA | $18.4 | 9.9% above |
ASMB has fallen below most of its moving averages, though it's still 9.9% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ASMB on trend strength, trading above more of its moving averages.
ASMB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $251.3 | $74.4 | -70% |
| 2021 | $74.4 | $27.2 | -63% |
| 2022 | $27.2 | $15.1 | -44% |
| 2023 | $15.1 | $9.84 | -35% |
| 2024 | $9.84 | $15.2 | +54% |
| 2025 | $15.2 | $33.6 | +122% |
| 2026 YTD | $33.6 | $20.2 | -40% |
ASMB's yearly returns have swung widely, from +122% in 2025 to −70% in 2020. It's down 40% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ASMB on returns for 2026, with the stronger performance.